Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
← catalyst calendarNCT07456826 · readout ≤ 12 d
Sponsored by Harrow Inc (industry) · HROW — their whole pipeline →.
Phase
Phase 4
Status
Enrolling by invitation
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
236estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-31 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetic Macular Edema (DME)
- Age-Related Macular Degeneration (AMD)
- Retinal Vein Occlusion
- Diabetic Retinopathy (DR)
Interventions
- Drug: Chloroprocaine Ophthalmic Gel 3% (IHEEZO)
- Procedure: Sham Subconjunctival Injection
- Drug: Proparacaine Hydrochloride Ophthalmic Solution 0.5%
- Drug: Lidocaine Hydrochloride Injection 2%
Primary outcome
what the primary-completion date above is the date OFProportion of Participants Achieving Successful Ocular Surface Anesthesia
measured Immediately before and immediately after intravitreal injection (Day 1)
Permalink · HROW's whole pipeline · Catalyst calendar · Every registered study · What changed